AxoGen (AXGN) Competitors

AxoGen (NASDAQ:AXGN) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Which has preferable earnings & valuation, AXGN or LMAT?

LeMaitre Vascular has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$194.52M	2.78	-$9.96M	-$0.15	-79.27
LeMaitre Vascular	$219.86M	8.60	$44.04M	$1.98	42.26

Which has more volatility & risk, AXGN or LMAT?

AxoGen has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in AXGN or LMAT?

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 2.8% of AxoGen shares are owned by insiders. Comparatively, 9.5% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Do analysts rate AXGN or LMAT?

AxoGen presently has a consensus price target of $24.50, suggesting a potential upside of 106.06%. LeMaitre Vascular has a consensus price target of $97.83, suggesting a potential upside of 16.91%. Given AxoGen's stronger consensus rating and higher probable upside, equities analysts plainly believe AxoGen is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the media favor AXGN or LMAT?

In the previous week, LeMaitre Vascular had 2 more articles in the media than AxoGen. MarketBeat recorded 4 mentions for LeMaitre Vascular and 2 mentions for AxoGen. AxoGen's average media sentiment score of 1.19 beat LeMaitre Vascular's score of 1.17 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is AXGN or LMAT more profitable?

LeMaitre Vascular has a net margin of 19.96% compared to AxoGen's net margin of -3.68%. LeMaitre Vascular's return on equity of 13.53% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-3.68%	-7.09%	-3.67%
LeMaitre Vascular	19.96%	13.53%	9.78%

Summary

LeMaitre Vascular beats AxoGen on 11 of the 16 factors compared between the two stocks.